Hansen Pharmaceutical hits daily limit up for fifth consecutive board

中国基金报··CN·Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Hansen Pharmaceutical surged to its daily limit up in early trading on August 25, with over 200,000 lots locked in, securing its fifth consecutive limit-up board. As of press time, the stock traded at 12.33 yuan per share, with turnover of 1.14 billion yuan and a latest market capitalization of 6.2 billion yuan. On the news front, the company released its 2026 interim report on August 24, showing first-half net profit attributable to the parent up 55.52% year on year, driven by its exclusive core products Simotang Oral Liquid and Tianma Xingnao Capsules, and benefiting from a sharp rebound in investment income from associates and a significant decline in income tax expenses. In early trading, the pharmaceutical sector saw localized movement, with innovative drug concept stocks strengthening. Xidian Pharmaceutical hit a 20% limit up, Jiheng Pharmaceutical and Hainan Haiyao surged to limit up, Yuheng Pharmaceutical touched limit up, Hengdi Pharmaceutical rose over 15%, and Chenxin Pharmaceutical, Longshen Rongfa, and Xinguang Pharmaceutical followed higher. The National Medical Products Administration recently held a meeting, calling for support for high-quality development of generic drugs, strengthening medication safeguards for special populations, and expanding high-level opening up.

Impact on assets 8